Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced that it has aligned with the U.S. Food and Drug Administration (FDA) to determine the appropriate dose of palazestrant for its pivotal clinical trials. The FDA has selected a 90 mg dose of palazestrant for both the Phase 3 OPERA-01 monotherapy trial and the Phase 3 OPERA-02 combination trial with ribociclib, focusing on ER+/HER2- metastatic breast cancer. This update will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The trials aim to address treatment resistance in metastatic breast cancer, and Olema anticipates top-line data from the OPERA-01 trial in 2026, with a potential commercial launch in 2027.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。